Investigative reporters from The Washington Post conducted an analysis of compounding pharmacies in 2013, and this article details their findings. Although compounded drug products are helpful and necessary for some patients, there are also risks associated with prescribing formulations that are not FDA-approved. The cases presented in this article show some of those dangers.
Read the full article here.
CaroSpir is the first and only FDA-approved oral suspension of the potassium-sparing diuretic spironolactone. Please visit www.CaroSpir.com to learn more.